- Home
- FBK vs BLTE Comparison
FBK vs BLTE Comparison
Compare FBK & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FBK
- BLTE
- Stock Information
- Founded
- FBK 1906
- BLTE 2018
- Country
- FBK United States
- BLTE United States
- Employees
- FBK N/A
- BLTE N/A
- Industry
- FBK Major Banks
- BLTE Biotechnology: Pharmaceutical Preparations
- Sector
- FBK Finance
- BLTE Health Care
- Exchange
- FBK Nasdaq
- BLTE Nasdaq
- Market Cap
- FBK 2.1B
- BLTE 2.1B
- IPO Year
- FBK 2016
- BLTE 2022
- Fundamental
- Price
- FBK $51.03
- BLTE $69.93
- Analyst Decision
- FBK Buy
- BLTE Strong Buy
- Analyst Count
- FBK 4
- BLTE 4
- Target Price
- FBK $58.50
- BLTE $96.67
- AVG Volume (30 Days)
- FBK 454.9K
- BLTE 45.0K
- Earning Date
- FBK 07-14-2025
- BLTE 08-11-2025
- Dividend Yield
- FBK 1.49%
- BLTE N/A
- EPS Growth
- FBK N/A
- BLTE N/A
- EPS
- FBK 1.94
- BLTE N/A
- Revenue
- FBK $410,807,000.00
- BLTE N/A
- Revenue This Year
- FBK $35.00
- BLTE N/A
- Revenue Next Year
- FBK $21.58
- BLTE N/A
- P/E Ratio
- FBK $26.33
- BLTE N/A
- Revenue Growth
- FBK N/A
- BLTE N/A
- 52 Week Low
- FBK $38.83
- BLTE $43.70
- 52 Week High
- FBK $58.88
- BLTE $86.53
- Technical
- Relative Strength Index (RSI)
- FBK 63.14
- BLTE 59.16
- Support Level
- FBK $46.95
- BLTE $68.99
- Resistance Level
- FBK $48.44
- BLTE $74.49
- Average True Range (ATR)
- FBK 0.98
- BLTE 3.27
- MACD
- FBK 0.10
- BLTE 0.48
- Stochastic Oscillator
- FBK 86.87
- BLTE 61.59
About FBK FB Financial Corporation
FB Financial Corp is a bank holding company. The company through its wholly-owned bank subsidiary provides commercial and consumer banking services to clients in select markets in Tennessee, North Alabama, and North Georgia. The company segment includes Banking and Mortgage. It generates revenue from the Banking segment which provides a full range of deposit and lending products and services to corporate, commercial, and consumer customers. The Mortgage segment includes the servicing of residential mortgage loans and the packaging and securitization of loans to governmental agencies.
About BLTE Belite Bio Inc
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.